Avoro Capital Advisors LLC
Q1 2024 13F-HR Holdings
Net value change ($000)
+1,333,757
(18.4%)
New positions
11
Sold out positions
7
Turnover %
21.4%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| VKTX | 294,380 | NEW |
| ALPINE IMMUNE SCIENCES, INC. | 228,921 | NEW |
| VERA | 227,027 | NEW |
| ARWR | 210,111 | 607.6% |
| SRPT | 143,497 | 34.3% |
| KRYS | 136,427 | 42.9% |
| ASND | 126,629 | 26.8% |
| RNAM | 125,938 | 554.4% |
| IOVA | 118,923 | 218.3% |
| MGNX | 90,528 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| Mirati Therapeutics, Inc. | -287,102 | -100.0% |
| CymaBay Therapeutics, Inc. | -262,444 | -100.0% |
| ALNY | -167,843 | -78.9% |
| GPCR | -95,107 | -100.0% |
| FOLD | -66,034 | -17.0% |
| Karuna Therapeutics, Inc. | -39,564 | -100.0% |
| BMRN | -33,367 | -8.0% |
| MLTX | -26,213 | -16.8% |
| ImmunoGen, Inc. | -25,944 | -100.0% |
| XENE | -17,057 | -6.5% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|